{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:03:51Z","timestamp":1792609431594,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bcp.2024.116376","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T02:38:52Z","timestamp":1718764732000},"page":"116376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0702-1395","authenticated-orcid":false,"given":"Joseph T.","family":"Coyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2024.116376_b0005","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1038\/s41598-021-88428-9","article-title":"Altered neural oscillations and behavior in a genetic mouse model of NMDA receptor hypofunction","volume":"11","author":"Aguilar","year":"2021","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bcp.2024.116376_b0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.biopsych.2011.05.017","article-title":"Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia","volume":"70","author":"Andreasen","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2024.116376_b0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.nbd.2011.10.006","article-title":"The NMDA receptor co-agonists, D-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex","volume":"45","author":"Balu","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"26","key":"10.1016\/j.bcp.2024.116376_b0020","doi-asserted-by":"crossref","first-page":"E2400","DOI":"10.1073\/pnas.1304308110","article-title":"Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction","volume":"110","author":"Balu","year":"2013","journal-title":"PNAS"},{"issue":"7","key":"10.1016\/j.bcp.2024.116376_b0025","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/mp.2008.130","article-title":"Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior","volume":"14","author":"Basu","year":"2009","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2024.116376_b0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0197-4580(94)90114-7","article-title":"D-cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats","volume":"5","author":"Baxter","year":"1994","journal-title":"Neurobiol. Aging"},{"issue":"Suppl 5","key":"10.1016\/j.bcp.2024.116376_b0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00004850-199501005-00008","article-title":"The content and context of compliance","volume":"9","author":"Bebbington","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116376_b0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nn.2447","article-title":"Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes","volume":"13","author":"Belforte","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2024.116376_b0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2020.01.025","article-title":"AMPA receptor subunit localization in schizophrenia anterior cingulate cortex","volume":"249","author":"Benesh","year":"2022","journal-title":"Schizophr. Res."},{"issue":"8049","key":"10.1016\/j.bcp.2024.116376_b0050","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(77)91542-2","article-title":"Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses","volume":"2","author":"Bird","year":"1977","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2024.116376_b0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.bcp.2024.116376_b0060","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.biopsych.2019.04.031","article-title":"Targeted treatment of individuals with psychosis carrying a copy number variant containing a genomic triplication of the glycine decarboxylase gene","volume":"86","author":"Bodkin","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.bcp.2024.116376_b0065","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2024.116376_b0070","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"Bugarski-Kirola","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"5544","key":"10.1016\/j.bcp.2024.116376_b0075","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1126\/science.1066969","article-title":"A paradigm shift in brain research","volume":"294","author":"Carlsson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116376_b0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.biopsycho.2015.10.013","article-title":"A quantitative review of the postmortem evidence for decreased cortical N-methyl-D-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits?","volume":"16","author":"Catts","year":"2016","journal-title":"Biol. Psychol."},{"issue":"10","key":"10.1016\/j.bcp.2024.116376_b0085","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/s41386-023-01660-x","article-title":"In memoriam: S. J. Enna, PhD, December 19, 1944-June 15, 2023","volume":"48","author":"Coyle","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2024.116376_b0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/HRP.0000000000000102","article-title":"History of the concept of disconnectivity in schizophrenia","volume":"24","author":"Coyle","year":"2016","journal-title":"Harv. Rev. Psychiatry"},{"issue":"12","key":"10.1016\/j.bcp.2024.116376_b0095","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1176\/appi.ajp.2020.20101481","article-title":"Fifty years of research on schizophrenia: The ascendance of the glutamatergic synapse","volume":"177","author":"Coyle","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116376_b0100","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3389\/fnins.2020.00927","article-title":"The discovery and characterization of targeted perikaryal-specific brain lesions with excitotoxins","volume":"14","author":"Coyle","year":"2020","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2024.116376_b0105","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/cells12040574","article-title":"Dysregulated signaling at postsynaptic density: A systematic review and translational appraisal for the pathophysiology, clinics, and antipsychotics' treatment of schizophrenia","volume":"12","author":"de Bartolomeis","year":"2023","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.bcp.2024.116376_b0110","first-page":"112","article-title":"Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)","volume":"110","author":"Delay","year":"1952","journal-title":"Ann. Med. Psychol. (Paris)"},{"issue":"4","key":"10.1016\/j.bcp.2024.116376_b0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/gepi.1034","article-title":"Unbiased methods for population-based association studies","volume":"21","author":"Devlin","year":"2001","journal-title":"Drugs. Genet Epidemiol."},{"issue":"21","key":"10.1016\/j.bcp.2024.116376_b0120","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1016\/j.neuron.2023.08.004","article-title":"Brain-region-specific changes in neurons and glia and dysregulation of dopamine signaling in Grin2a mutant mice","volume":"111","author":"Farsi","year":"2023","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.bcp.2024.116376_b0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00213-004-2032-2","article-title":"A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients","volume":"179","author":"Goff","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.bcp.2024.116376_b0130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/schbul\/sbx199","article-title":"The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention","volume":"45","author":"Grace","year":"2019","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.bcp.2024.116376_b0135","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.bmb.a011565","article-title":"Advances in post mortem molecular neurochemistry and neuropathology: examples from schizophrenia research","volume":"52","author":"Harrison","year":"1996","journal-title":"Br. Med. Bull."},{"issue":"Pt 4","key":"10.1016\/j.bcp.2024.116376_b0140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/brain\/122.4.593","article-title":"The neuropathology of schizophrenia. A critical review of the data and their interpretation","volume":"122","author":"Harrison","year":"1999","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.bcp.2024.116376_b0145","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41398-023-02393-7","article-title":"Mouse mutants in schizophrenia risk genes GRIN2A and AKAP11 show EEG abnormalities in common with schizophrenia patients","volume":"13","author":"Herzog","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116376_b0150","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1055\/s-0028-1114024","article-title":"Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man","volume":"87","author":"Hornykiewicz","year":"1962","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"3","key":"10.1016\/j.bcp.2024.116376_b0155","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2024.116376_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.524258","article-title":"Multiple rare risk coding variants in postsynaptic density-related genes associated with schizophrenia susceptibility","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Genet."},{"issue":"10202","key":"10.1016\/j.bcp.2024.116376_b0165","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2024.116376_b0170","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1440-1789.2007.00798.x","article-title":"Neuropathology of schizophrenia: a mini review","volume":"27","author":"Iritani","year":"2007","journal-title":"Neuropathology"},{"issue":"7","key":"10.1016\/j.bcp.2024.116376_b0175","first-page":"841","volume":"17","author":"Janssen","year":"1967","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.bcp.2024.116376_b0180","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(76)90890-4","article-title":"Cerebral ventricular size and cognitive impairment in chronic schizophrenia","volume":"2","author":"Johnstone","year":"1976","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2024.116376_b0185","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199346040-00002","article-title":"Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential","volume":"46","author":"Kane","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2024.116376_b0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","article-title":"Unique effects of clozapine: A pharmacological perspective","volume":"82","author":"Khokhar","year":"2018","journal-title":"Adv. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116376_b0195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/mp.2011.154","article-title":"De novo CNV analysis implicates specific abnormalities of postsynaptic signaling complexes in the pathogenesis of schizophrenia","volume":"17","author":"Kirov","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2024.116376_b0200","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/oxfordjournals.schbul.a007078","article-title":"The global costs of schizophrenia","volume":"30","author":"Knapp","year":"2004","journal-title":"Schizophr. Bull."},{"issue":"12","key":"10.1016\/j.bcp.2024.116376_b0205","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jamapsychiatry.2014.1582","article-title":"Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder","volume":"71","author":"Konopaske","year":"2014","journal-title":"JAMA Psychiat."},{"issue":"9","key":"10.1016\/j.bcp.2024.116376_b0210","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/archpsyc.60.9.878","article-title":"Regionally localized thinning of the cerebral cortex in schizophrenia","volume":"60","author":"Kuperberg","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.bcp.2024.116376_b0215","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1176\/appi.ps.52.8.1039","article-title":"Some perspectives on deinstitutionalization","volume":"52","author":"Lamb","year":"2001","journal-title":"Psychiatr. Serv."},{"issue":"10","key":"10.1016\/j.bcp.2024.116376_b0220","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116376_b0225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2015.02.012","article-title":"Perspectives on the mGluR2\/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?","volume":"60","author":"Li","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116376_b0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1192\/bjp.151.2.145","article-title":"The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy","volume":"151","author":"Liddle","year":"1987","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116376_b0235","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2024.116376_b0240","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). International Suicide Prevention Trial Study Group","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.bcp.2024.116376_b0245","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"Suppl B","key":"10.1016\/j.bcp.2024.116376_b0250","first-page":"47","article-title":"An overview of the mechanism of action of clozapine","volume":"55","author":"Meltzer","year":"1994","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.bcp.2024.116376_b0255","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","article-title":"Clozapine-induced agranulocytosis","volume":"99","author":"Mijovic","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcp.2024.116376_b0260","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","article-title":"Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up","volume":"162","author":"Milev","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.bcp.2024.116376_b0265","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/schbul\/sbs075","article-title":"Capturing the angel in \u201cangel dust\u201d: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans","volume":"38","author":"Moghaddam","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"11 Suppl 2","key":"10.1016\/j.bcp.2024.116376_b0270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1017\/S1092852900008166","article-title":"Factors in antipsychotic drug selection: tolerability considerations","volume":"8","author":"Nasrallah","year":"2003","journal-title":"CNS Spectr."},{"key":"10.1016\/j.bcp.2024.116376_b0275","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/archpsyc.1964.01720210028005","article-title":"Phenothiazine treatment in acute schizophrenia","volume":"10","author":"National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group","year":"1964","journal-title":"Arch. Gen. Psychiat."},{"issue":"6558","key":"10.1016\/j.bcp.2024.116376_b0280","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/378665a0","article-title":"Schizophrenia. All out for chromosome six","volume":"378","author":"Peltonen","year":"1995","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2024.116376_b0285","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/HRP.0000000000000046","article-title":"Deinstitutionalization of American public hospitals for the mentally ill before and after the introduction of antipsychotic medications","volume":"23","author":"Pow","year":"2015","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116376_b0290","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.ai.2017.06.004","article-title":"Complement system in neural synapse elimination in development and disease","volume":"135","author":"Presumey","year":"2017","journal-title":"Adv. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116376_b0295","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/adb.12577","article-title":"N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse","volume":"24","author":"Puhl","year":"2019","journal-title":"Addict. Biol."},{"key":"10.1016\/j.bcp.2024.116376_b0300","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.nbd.2014.10.009","article-title":"In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia","volume":"73","author":"Puhl","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.bcp.2024.116376_b0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010989","article-title":"Investigating trait variability of gene co-expression network architecture in brain by controlling for genomic risk of schizophrenia","volume":"19","author":"Radulescu","year":"2023","journal-title":"PLoS Genet."},{"issue":"3","key":"10.1016\/j.bcp.2024.116376_b0310","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archpsyc.55.3.215","article-title":"Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease","volume":"55","author":"Rajkowska","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116376_b0315","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/archpsyc.57.4.349","article-title":"Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings","volume":"57","author":"Rosoklija","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116376_b0320","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2024.116376_b0325","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1096-9861(19980316)392:3<402::AID-CNE9>3.0.CO;2-5","article-title":"Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method","volume":"392","author":"Selemon","year":"1998","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.bcp.2024.116376_b0330","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","article-title":"Rare coding variants in ten genes confer substantial risk for schizophrenia","volume":"604","author":"Singh","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2024.116376_b0335","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1176\/ajp.133.2.197","article-title":"The dopamine hypothesis of schizophrenia: focus on the dopamine receptor","volume":"133","author":"Snyder","year":"1976","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.bcp.2024.116376_b0340","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/mp.2017.47","article-title":"Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia","volume":"22","author":"Steullet","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"7906","key":"10.1016\/j.bcp.2024.116376_b0345","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116376_b0350","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/138161210790361452","article-title":"Strategies to enhance N-methyl-D- aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis","volume":"16","author":"Tsai","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"10.1016\/j.bcp.2024.116376_b0355","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/archpsyc.1995.03950220039008","article-title":"Abnormal excitatory neurotransmitter metabolism in schizophrenic brains","volume":"52","author":"Tsai","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116376_b0360","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1192\/bjp.160.5.687","article-title":"Ventricular enlargement in schizophrenia. A meta-analysis of studies of the ventricle:brain ratio (VBR)","volume":"160","author":"Van Horn","year":"1992","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.bcp.2024.116376_b0365","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.biopsych.2018.04.023","article-title":"Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium","volume":"84","author":"van Erp","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.bcp.2024.116376_b0370","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/2040-2392-5-38","article-title":"Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders","volume":"4","author":"Wesseling","year":"2014","journal-title":"Mol. Autism"},{"issue":"2","key":"10.1016\/j.bcp.2024.116376_b0375","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/schbul\/sbq002","article-title":"Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia","volume":"36","author":"Wonodi","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.bcp.2024.116376_b0380","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ajhp\/57.3.238","article-title":"Atypical antipsychotic agents: a critical review","volume":"57","author":"Worrel","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.bcp.2024.116376_b0385","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41593-020-00763-8","article-title":"Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice","volume":"24","author":"Yilmaz","year":"2021","journal-title":"Nat. Neurosci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:18:59Z","timestamp":1731457139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224003599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":77,"alternative-id":["S0006295224003599"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116376","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116376"}}